Developing Treatments for Hyperarousal in a Model System

在模型系统中开发过度觉醒的治疗方法

基本信息

  • 批准号:
    9223738
  • 负责人:
  • 金额:
    $ 37万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-02-16 至 2019-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): PTSD is a major health problem for military and civilian populations and treatment has proven to be less than effective. There are many people exposed to trauma who suffer flashbacks, bad dreams, numbing, fear, anxiety, sleeplessness, hyper-vigilance, hyperarousal, and an inability to cope. Current behavioral and drug treatment strategies are based on fear conditioning and are capable of treating only some of the symptoms of PTSD because the extinction of fear does not deal with the various forms of hyperarousal experienced by people with PTSD. The inability to treat more of the symptoms of PTSD is a major problem for the field. To help address this problem, researchers have developed animal models of PTSD but many of these models suffer from several limitations. First, they focus on extinguishing the fear associated with trauma without assessing or treating the hyperarousal caused by trauma. Second, they rely on group data, and it is clear that not everyone exposed to trauma develops PTSD. We have developed an animal model of PTSD in which conditioning and hyperarousal can be extinguished. The model is based on observations that the nictitating membrane response becomes exaggerated as a function of pairing a tone and shock. This exaggerated response occurs when the shock is tested by itself (without the tone) and is a form of hyperarousal termed conditioning-specific reflex modification (CRM). CRM is detected by comparing responses to a range of US intensities by themselves before and after classical conditioning. We now have strong evidence we can "treat" CRM as well as extinguish CRs which uniquely positions us to address two core features of PTSD and examine the relationship between them. Importantly, high levels of CRM only occur in 15-25 percent of rabbits exposed to tone-shock pairings - levels consistent with the incidence of PTSD. The current renewal will use our model of PTSD to test three specific aims that will move between the bench and the bedside to: (1) Determine the characteristics of CRM treatment that predict PTSD symptom treatment by uncovering better ways to extinguish CRM; (2) Understand the mechanisms underlying CRM treatment by inactivating areas key to executing responses and using drugs that treat PTSD to better understand CRM; and (3) Locate and characterize neural substrates of CRM treatment to develop targets for PTSD symptom treatment. These aims are designed to meet our goal of providing clinical approaches to treating PTSD.
描述(由申请人提供):创伤后应激障碍是军人和平民的主要健康问题,治疗已被证明效果不佳。有许多人暴露在创伤中,他们遭受闪回,噩梦,麻木,恐惧,焦虑,失眠,过度警惕,过度觉醒和无法科普。目前的行为和药物治疗策略是基于恐惧条件反射,并且只能治疗PTSD的一些症状,因为恐惧的消失不能处理PTSD患者经历的各种形式的过度觉醒。无法治疗更多的PTSD症状是该领域的一个主要问题。为了帮助解决这个问题,研究人员已经开发了PTSD的动物模型,但这些模型中的许多都受到一些限制。首先,他们专注于消除与创伤相关的恐惧,而没有评估或治疗创伤引起的过度觉醒。其次,他们依赖于群体数据,很明显,并不是每个暴露于创伤的人都会患上创伤后应激障碍。我们已经建立了一个创伤后应激障碍的动物模型,在这个模型中,条件反射和过度觉醒可以被消除。该模型是基于瞬膜反应成为一个函数的配对音调和冲击夸大的观察。当电击本身被测试时(没有音调),这种夸张的反应就会发生,这是一种被称为条件反射修正(CRM)的过度觉醒形式。通过比较经典条件反射前后对一系列US强度的反应来检测CRM。我们现在有强有力的证据表明,我们可以“治疗”CRM并消除CR,这使我们能够独特地解决创伤后应激障碍的两个核心特征并研究它们之间的关系。重要的是,高水平的CRM只发生在15- 25%的兔子暴露于色调休克配对-水平与创伤后应激障碍的发病率一致。目前的更新将使用我们的PTSD模型来测试三个具体的目标,这些目标将在实验室和床边之间移动:(1)通过发现更好的消除CRM的方法来确定CRM治疗的特征,从而预测PTSD症状的治疗;(2)通过灭活执行响应的关键区域和使用治疗PTSD的药物来更好地理解CRM,从而了解CRM治疗的机制;以及(3)定位和表征CRM治疗的神经基质以开发PTSD症状治疗的靶点。这些目标旨在满足我们提供治疗PTSD的临床方法的目标。

项目成果

期刊论文数量(14)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Effects of systemic glutamatergic manipulations on conditioned eyeblink responses and hyperarousal in a rabbit model of post-traumatic stress disorder.
  • DOI:
    10.1097/fbp.0000000000000333
  • 发表时间:
    2017-10
  • 期刊:
  • 影响因子:
    1.6
  • 作者:
    Burhans LB;Smith-Bell CA;Schreurs BG
  • 通讯作者:
    Schreurs BG
Unpaired extinction: implications for treating post-traumatic stress disorder.
  • DOI:
    10.1016/j.jpsychires.2010.10.010
  • 发表时间:
    2011-05
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Schreurs BG;Smith-Bell CA;Burhans LB
  • 通讯作者:
    Burhans LB
Delayed unpaired extinction as a treatment for hyperarousal of the rabbit nictitating membrane response and its implications for treating PTSD.
延迟不成对消退作为兔子瞬膜反应过度唤醒的治疗方法及其对治疗创伤后应激障碍(PTSD)的影响。
  • DOI:
    10.1016/j.jpsychires.2018.01.007
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Schreurs,BernardG;Smith-Bell,CarrieA;Burhans,LaurenB
  • 通讯作者:
    Burhans,LaurenB
Classical conditioning and conditioning-specific reflex modification of rabbit heart rate as a function of unconditioned stimulus location.
兔子心率的经典条件反射和条件特异性反射修正作为无条件刺激位置的函数。
  • DOI:
    10.1037/a0024325
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    1.9
  • 作者:
    Schreurs,BernardG;Smith-Bell,CarrieA;Burhans,LaurenB
  • 通讯作者:
    Burhans,LaurenB
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BERNARD G. SCHREURS其他文献

BERNARD G. SCHREURS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BERNARD G. SCHREURS', 18)}}的其他基金

Dietary manipulations in rabbits induce the cellular, neuropathological, and cognitive hallmarks of late-onset Alzheimer's Disease
兔子的饮食控制会诱发迟发性阿尔茨海默病的细胞、神经病理和认知特征
  • 批准号:
    10668423
  • 财政年份:
    2021
  • 资助金额:
    $ 37万
  • 项目类别:
Dietary manipulations in rabbits induce the cellular, neuropathological, and cognitive hallmarks of late-onset Alzheimer's Disease
兔子的饮食控制会诱发迟发性阿尔茨海默病的细胞、神经病理和认知特征
  • 批准号:
    10468188
  • 财政年份:
    2021
  • 资助金额:
    $ 37万
  • 项目类别:
Dietary manipulations in rabbits induce the cellular, neuropathological, and cognitive hallmarks of late-onset Alzheimer's Disease
兔子的饮食控制会诱发迟发性阿尔茨海默病的细胞、神经病理和认知特征
  • 批准号:
    10269381
  • 财政年份:
    2021
  • 资助金额:
    $ 37万
  • 项目类别:
Susceptibility and Resilience to Adverse Childhood Experiences: A Role for Perineuronal Nets
对童年不良经历的敏感性和恢复力:神经周围网络的作用
  • 批准号:
    10667529
  • 财政年份:
    2020
  • 资助金额:
    $ 37万
  • 项目类别:
Susceptibility and Resilience to Adverse Childhood Experiences: A Role for Perineuronal Nets
对童年不良经历的敏感性和恢复力:神经周围网络的作用
  • 批准号:
    10221013
  • 财政年份:
    2020
  • 资助金额:
    $ 37万
  • 项目类别:
Susceptibility and Resilience to Adverse Childhood Experiences: A Role for Perineuronal Nets
对童年不良经历的敏感性和恢复力:神经周围网络的作用
  • 批准号:
    10458512
  • 财政年份:
    2020
  • 资助金额:
    $ 37万
  • 项目类别:
Cholesterol and Copper Affect Learning and Memory
胆固醇和铜影响学习和记忆
  • 批准号:
    9085605
  • 财政年份:
    2015
  • 资助金额:
    $ 37万
  • 项目类别:
An animal model for developing treatments of PTSD core features
用于开发 PTSD 核心特征治疗方法的动物模型
  • 批准号:
    8206616
  • 财政年份:
    2009
  • 资助金额:
    $ 37万
  • 项目类别:
Developing Treatments for Hyperarousal in a Model System
在模型系统中开发过度觉醒的治疗方法
  • 批准号:
    8641414
  • 财政年份:
    2009
  • 资助金额:
    $ 37万
  • 项目类别:
Plasticity in deep cerebellar nuclei as a function of classical conditioning
小脑深部核团的可塑性作为经典条件反射的函数
  • 批准号:
    7844830
  • 财政年份:
    2009
  • 资助金额:
    $ 37万
  • 项目类别:

相似海外基金

Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8358448
  • 财政年份:
    2012
  • 资助金额:
    $ 37万
  • 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8517552
  • 财政年份:
    2012
  • 资助金额:
    $ 37万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7952159
  • 财政年份:
    2009
  • 资助金额:
    $ 37万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7952152
  • 财政年份:
    2009
  • 资助金额:
    $ 37万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7719194
  • 财政年份:
    2008
  • 资助金额:
    $ 37万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7605416
  • 财政年份:
    2007
  • 资助金额:
    $ 37万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7605425
  • 财政年份:
    2007
  • 资助金额:
    $ 37万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7378753
  • 财政年份:
    2006
  • 资助金额:
    $ 37万
  • 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
  • 批准号:
    6825160
  • 财政年份:
    2004
  • 资助金额:
    $ 37万
  • 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
  • 批准号:
    2702283
  • 财政年份:
    1997
  • 资助金额:
    $ 37万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了